Injectable discogenic cell therapy - DiscGenics

Drug Profile

Injectable discogenic cell therapy - DiscGenics

Alternative Names: IDCT

Latest Information Update: 05 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DiscGenics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Intervertebral disc degeneration
  • Preclinical Spinal disorders

Most Recent Events

  • 31 May 2018 DiscGenics collaborates with CCRM and GE Healthcare for scale-up of Injectable discogenic cell therapy
  • 29 Mar 2018 Preclinical trials in Intervertebral disc degeneration in Japan (Parenteral), before March 2018 (DiscGenics website, March 2018)
  • 29 Mar 2018 Preclinical trials in Spinal disorders in USA (Parenteral), before March 2018 (DiscGenics website, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top